Research for poly(ADP-ribosylation) as a potential cancer therapeutic target

2014 Fiscal Year Final Research Report

• Project/Area Number: 22300343
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Clinical oncology
• Research Institution: National Cancer Center Japan
• Principal Investigator: MASUTANI MITSUKO 独立行政法人国立がん研究センター, その他部局等, その他 (60238904)
• Co-Investigator(Renkei-kenkyūsha): OKAYASU Ryuichi 放射線医学総合研究所, 放射線防護研究センター, Senior Researcher (50356135) ; FUJIMORI Hiroaki 国立がん研究センター研究所, 創薬臨床研究分野, 研究員 (00590043)
• Project Period (FY): 2010-04-01 – 2015-03-31
• Keywords: PARP / PARG / NAD / gamma-irradiation / cancer

Outline of Final Research Achievements

Poly(ADP-ribosylation) reaction is catalyzed by poly(ADP-ribose) polymerase, PARP-1, PARP-2, PARP-3 and other PARP family proteins and is involved in DNA repair response, chromatin regulation, and cell death. We analyzed the sensitivity restricting genes for PARP inhibitors and their mechanisms. We also analyzed the effects of PARP inhibitors on epigenome regulation. Poly(ADP-ribose) glycohydrolase (PARG )is a major enzyme for poly(ADP-ribose) degradation and participates in DNA damage response. We studied the possibility of PARG inhibitors as a cancer therapeutic agent using biochemical strategies.

Free Research Field

薬学、生化学、腫瘍学、分子生物学